Format

Send to

Choose Destination
World J Urol. 2003 May;21(1):21-7. Epub 2003 Mar 8.

The selenium and vitamin E cancer prevention trial.

Author information

1
Section of Urologic Oncology, Urological Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, OH 44195, Cleveland, USA. kleine@ccf.org

Abstract

BACKGROUND:

Evidence suggests that both selenium and vitamin E reduce the risk of prostate cancer. The Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a randomized, prospective, double-blind study designed to determine whether selenium and vitamin E alone and in combination can reduce the risk of prostate cancer among healthy men.

MATERIALS AND METHODS:

The preclinical and epidemiological evidence supporting a role for selenium and vitamin E as chemopreventive agents in prostate cancer are reviewed, and details of the trial design are presented. RESULTS. Preclinical, epidemiological, and phase III data from randomized, placebo-controlled clinical trials suggest that both selenium and vitamin E have potential efficacy in prostate cancer prevention. SELECT is a 2x2 factorial study with an accrual goal of 32,400 men with nonsuspicious DRE and serum PSA of 4 ng/ml or lower.

CONCLUSIONS:

SELECT is the second large-scale study of chemoprevention for prostate cancer. Enrollment began in 2001 with final results anticipated in 2013.

PMID:
12756490
DOI:
10.1007/s00345-002-0314-z
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center